You would like to read
- Glenmark Pharmaceuticals receives USFDA approval for Clindamycin Phosphate Gel
- Glenmark Pharma gets USFDA nod for acne treatment drug
- Glenmark Pharmaceuticals receives ANDA approval for Tacrolimus Capsules USP, 0.5 mg, 1 mg and 5 mg
- Alembic Pharmaceuticals' JV receives UDFDA tentative approval for Testosterone Gel
Mumbai (Maharashtra) [India], February 11 (ANI/PRNewswire): Glenmark Pharmaceuticals Limited (Glenmark) has received final approval by the United States Food and Drug Administration (U.S. FDA) for Clindamycin Phosphate Gel USP, 1 per cent, the generic version of Cleocin T® Gel, 1 per cent, of Pharmacia and Upjohn.
According to IQVIATM sales data for the 12 month period ending December 2020, the Cleocin T® Gel, 1 per cent market achieved annual sales of approximately USD 73.8 million.
Glenmark's current portfolio consists of 169 products authorized for distribution in the US marketplace and 42 ANDA's pending approval with the US FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
This story is provided by PRNewswire. ANI will not be responsible in any way for the content of this article. (ANI/PRNewswire)
DISCLAIMER
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
